Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone Deficiency
Authors:
Open Access
- 22 April 2025
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (6) , 2853-2873
Abstract
Introduction Adult growth hormone deficiency (GHD) is an endocrine disorder associated with increased morbidity and poor quality of life. The purpose of this study was to describe the clinical characteristics, treatment patterns, and prevalence of individuals at risk for adult GHD and individuals with confirmed adult GHD in the United States (US). Methods Using Veradigm Network electronic health records linked to claims, this study identified adults with a high likelihood of adult GHD based on having ≥ 1 of the following between January 1, 2017 and December 31, 2021: diagnosis of hypopituitarism or ≥ 1 related condition, such as Cushing disease, ≥ 3 pituitary hormone deficiencies other than GHD, ≥ 3 pituitary hormone treatments other than growth hormone (GH), or ≥ 1 prescription for GH. Index date was the earliest qualifying event. Individuals were stratified by GH level on or before index date: confirmed adult GHD (< 3 ng/mL), at risk for adult GHD (no test result), ruled-out (≥ 3 ng/mL). Results US prevalence of adult GHD was estimated to be between 0.2 (confirmed) and 37.0 (confirmed + at-risk) per 100,000. Among 268 individuals with confirmed adult GHD and 54,310 at risk for adult GHD, mean age was 50 years old, and a majority were female. GH treatment was initiated in 9.7% of confirmed individuals and 3.1% of those at risk for adult GHD. Among confirmed and at-risk individuals, prevalence of endocrine-related conditions was higher in treated individuals, whereas prevalence of several metabolic and cardiovascular comorbidities was higher in those untreated. Only 32.2% of individuals who initiated treatment during the follow-up period were persistent until the end of follow-up. Conclusions Our findings report US prevalence of adult GHD and suggest that adult GHD is commonly underdiagnosed in the US. Factors contributing to low rates of adult GHD diagnosis and treatment warrant further research.Keywords
Funding Information
- Ascendis Pharma
This publication has 33 references indexed in Scilit:
- Changing Patterns of the Adult Growth Hormone Deficiency Diagnosis Documented in a Decade-Long Global Surveillance DatabaseThe Journal of Clinical Endocrinology & Metabolism, 2009
- Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of AustraliaEuropean Journal of Endocrinology, 2007
- HypopituitarismThe Lancet, 2007
- Incidence of GH deficiency – a nationwide studyEuropean Journal of Endocrinology, 2006
- Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Comparison of Normative Reference Data for the General Population of England and Wales with Results for Adult Hypopituitary Patients with Growth Hormone DeficiencyHormone Research in Paediatrics, 2005
- Fracture risk is increased in patients with GH deficiency or untreated prolactinomas – a case‐control studyClinical Endocrinology, 2002
- Which Patients Do Not Require a GH Stimulation Test for the Diagnosis of Adult GH Deficiency?The Journal of Clinical Endocrinology & Metabolism, 2002
- Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern SpainClinical Endocrinology, 2001
- Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial.The Journal of Clinical Endocrinology & Metabolism, 1995
- The growth hormone deficiency syndrome in adultsClinical Endocrinology, 1992